Source: International Congress 2018 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Wang (Taoyuan, Taiwan), C. Lo (Taoyuan, Taiwan), H. Kuo (Taoyuan, Taiwan). A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma (SAA) after withdrawal of Omalizumab therapy. 1694

Member's Comments

No comment yet.

Related content which might interest you: Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE) Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Clinical effect of clean air administered directly to the breathing zone (airsonett airshower®) on perennial allergic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 353s Year: 2007 Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Is the asthma control questionnaire (ACQ) usefull during acute moderate to severe (AMS) asthma exacerbations (AE)? Source: Eur Respir J 2004; 24: Suppl. 48, 591s Year: 2004 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial Source: Annual Congress 2009 - Treatment beyond inhalers Year: 2009 High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 The utility of the impulse oscillometry system (IOS) in assessing bronchodilator responsiveness in patients with asthma and allergic rhinitis (AR Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Combination of electronically controlled breathing pattern and improved nebulizer technology for inhaled corticosteroid therapy of severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR) Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 The profile of poor ICS adherence in uncontrolled moderate to severe asthma. Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008